Genentech, Inc.

Other

F. Hoffmann-la Roche Ag

Pascal Pierre Alexandre Savy

Stephen Colin Price

Daniel P Sutherlin

Brian Salvatore Safina

Zachary Kevin Sweeney

Robert Andrew Heald

Matthew C Lucas

Georgette M Castanedo

David Goldstein

Rama Kondru

Wylie Palmer

Bryan K Chan

Joseph P Lyssikatos

Bohdan Waszkowycz

Philip Jackson

The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. 

Bicyclic heterocycles as MEK kinase inhibitors

Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Heterocyclic compounds and methods of use

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, or (iv) Xis CRand Xis O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use

The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.(Formula I) 

8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, or (iv) Xis CRand Xis O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Formula I (Ia and Ib) compounds wherein (i) Xis N and Xis S, (ii) Xis CRand Xis S, (iii) Xis N and Xis NR, (iv) Xis CRand Xis O, or (v) Xis CRand Xis NR, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. 

Growing community of inventors

Harlow, United Kingdom

Pascal Pierre Alexandre Savy